| Jan-23-15 06:24AM | Coverage initiated on Sarepta Therapeutics by RBC Capital Mkts Briefing.com |
| Jan-20-15 12:32PM | INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Sarepta Therapeutics, Inc. Business Wire |
| Jan-16-15 01:20PM | BioMarin CEO Angers Sarepta CEO With Slides Comparing Trial Data at The Wall Street Journal |
| Jan-15-15 04:30PM | Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - Analyst Blog Zacks |
| Jan-14-15 02:57PM | Sarepta's CEO can reverse the company's downward trend with a stellar presentation tomorrow at American City Business Journals +5.34% |
| 12:43PM | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT PR Newswire |
| 08:30AM | Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in Duchenne Muscular Dystrophy Patients Business Wire |
| Jan-13-15 11:46AM | Chimerix tackles Ebola outbreak CNBC |
| Jan-12-15 04:23PM | Taking Stock: Winners and Losers, Stock of the Day at Bloomberg -14.62% |
| 12:51PM | Sarepta Therapeutics (SRPT) Stock Hits One-Year Low Today After Eteplirsen Update at TheStreet |
| 09:47AM | Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year at TheStreet |
| 08:13AM | Sarepta Therapeutics Falls Following 6-Minute Walk Test Results Benzinga |
| 07:09AM | SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or EDGAR Online |
| 07:00AM | Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy Business Wire |
| Jan-07-15 10:47AM | Sarepta Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors Business Wire +5.81% |
| Jan-05-15 07:00AM | Sarepta Therapeutics to Present Company Overview at the 2015 33rd Annual J.P. Morgan Healthcare Conference Business Wire |
| Jan-02-15 12:39PM | SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 Business Wire |
| Dec-31-14 04:30PM | Stull, Stull & Brody Announces the Investigation of Possible Breaches of Fiduciary Duties of Officers and Directors of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) GlobeNewswire |
| Dec-29-14 03:55PM | SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT GlobeNewswire |
| 12:45PM | Former CSO at Sarepta lands new job as head of Cambridge biotech startup at bizjournals.com |
| Dec-24-14 03:52PM | SECURITIES ALERT: Rosen Law Firm Reminds Sarepta Therapeutics, Inc. Investors of Important Deadline in Class Action Seeking to Recover Investor Losses - SRPT GlobeNewswire |
| Dec-16-14 05:46PM | SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT Marketwired |
| Dec-09-14 05:35PM | EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Against Sarepta Therapeutics, Inc. to Recover Investor Losses -- SRPT GlobeNewswire +6.46% |
| 03:32PM | SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT GlobeNewswire |
| Dec-08-14 06:45PM | INVESTOR ALERT: Class Action Lawsuit Against Sarepta Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP Business Wire |
| Dec-05-14 06:00AM | Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta at TheStreet |
| Dec-02-14 11:00AM | Sarepta DMD Community Update Call scheduled for 11:00 am ET today CCBN |
| Nov-24-14 05:24PM | It was another slow, low volume, lackluster trading session Yahoo Finance Blogs +5.59% |
| 04:30PM | Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on December 2, 2014 Business Wire |
| 12:26PM | Midday movers: 3D Systems, Kate Spade, Nike & more at CNBC |
| 12:20PM | BioMarin's Prosensa Buy: A 'Courageous' Acquisition? at Barrons.com |
| 10:22AM | BioMarin Buys Prosensa Backs Up Troubled Drug at Investor's Business Daily |
| 09:19AM | Stock Futures Trending Higher; Kate Spade Bags An Upgrade at Investor's Business Daily |
| 07:00AM | Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Business Wire |
| Nov-18-14 03:24PM | Robbins Arroyo LLP Is Investigating the Officers and Directors of Sarepta Therapeutics, Inc. (SRPT) on Behalf of Shareholders PR Newswire |
| 09:15AM | Sarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant Patients with Duchenne Muscular Dystrophy Business Wire |
| Nov-14-14 06:16PM | INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Sarepta Therapeutics, Inc. (SRPT) To Contact The Firm PR Newswire |
| 01:04PM | SAREPTA THERAPEUTICS, INC. Financials EDGAR Online Financials |
| Nov-13-14 04:40PM | Sarepta Initiates Dosing for Study Evaluating Eteplirsen Zacks |
| 10:21AM | A Day Of Reckoning Approaches For Merck And Its Critics at Forbes |
| Nov-12-14 05:15PM | Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy Business Wire |
| Nov-11-14 10:32AM | INVESTOR ALERT: Investigation of Sarepta Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP Business Wire |
| Nov-10-14 04:14PM | SHAREHOLDER ALERT: Investigation on Behalf of Sarepta Therapeutics, Inc. Investors Announced by Law Offices of Howard G. Smith Business Wire |
| 11:40AM | Sarepta Q3 Loss Narrower-Than-Expected, Eteplirsen in Focus Zacks |
| Nov-09-14 07:09PM | 10-Q for Sarepta Therapeutics, Inc. Company Spotlight |
| Nov-06-14 08:00AM | Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today CCBN +7.19% |
| 07:51AM | Sarepta Therapeutics tops 3Q profit forecasts AP |
| 07:09AM | SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online |
| 07:07AM | Q3 2014 Sarepta Therapeutics Inc Earnings Release - Before Market Open CCBN |
| 07:00AM | Sarepta Therapeutics Announces Third Quarter 2014 Financial Results and Recent Corporate Developments Business Wire |
| 06:31AM | SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 05:57AM | Investors eye earnings from film giants, biotech firms CNBC |
| Nov-05-14 05:56AM | Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT) Zacks -7.39% |
| Nov-04-14 07:00AM | Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Business Wire |
| 04:30AM | Tekmira Shares Surge Amid Promise of Ebola Treatment at Bloomberg |
| Oct-31-14 04:24PM | The rally that keeps on giving! Yahoo Finance Blogs |
| 03:30PM | Sarepta Therapeutics to Announce Third Quarter 2014 Financial Results and Corporate Update on November 6, 2014 Business Wire |
| 01:59PM | A 'Strange Back and Forth' Between Sarepta and the FDA at The Wall Street Journal |
| 06:40AM | Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx at TheStreet |
| Oct-30-14 08:58PM | [$$] FDA Comments on Sarepta Drug Talks at The Wall Street Journal |
| Oct-28-14 04:42PM | Twitter and Amgen are big market movers AP |
| 02:10PM | Sarepta Slumps as Eteplirsen NDA Submission Gets Delayed Zacks |
| 10:07AM | Story Stocks from Briefing.com Briefing.com |
| 06:46AM | Sarepta Slumps: SRPT Plunges 32.5% in Session Zacks |
| 12:56AM | [$$] Sareptas Muscular Dystrophy Drug Suffers Setback at The Wall Street Journal |
| Oct-27-14 06:06PM | Nasdaq stocks posting largest percentage decreases AP -32.47% |
| 05:46PM | Prosensa pops on Sarepta FDA delay CNBC |
| 04:34PM | S&P 500 trades in a narrow range, up against key technical levels Yahoo Finance Blogs |
| 04:26PM | Merck good medicine? Talking Numbers |
| 03:15PM | Market losers: Sarepta & Tesla CNBC |
| 02:51PM | Sarepta Gets Delayed And The Stock Gets Drilled Benzinga |
| 01:20PM | [$$] Muscular Dystrophy Drug Suffers Setback at The Wall Street Journal |
| 01:15PM | Petrobras Plunges In The Wake Of Brazilian Election Results at TheStreet |
| 12:29PM | 3 Stocks, 3 trades: MRK, GRMN & SRPT CNBC |
| 12:27PM | Sarepta Needs FDA Expertise, Stat at Forbes |
| 11:41AM | Sarepta price target slashed by Piper Jaffray at MarketWatch |
| 11:29AM | Sarepta Therapeutics: Don't Catch This Falling Knife at Barrons.com |
| 11:10AM | Sarepta Faces Major Hurdle, and Not From Ebola at 24/7 Wall St. |
| 11:02AM | Sarepta Shares Falls on Duchenne Drug Approval Filing Delay at TheStreet |
| 10:54AM | Sarepta tumbles on new delay for key drug AP |
| 09:47AM | Stocks to Watch: Chiquita, Allergan, Merck at The Wall Street Journal |
| 09:02AM | Valeant may up bid for Allergan...again; Merck mixed results; Apple Pay mobile payment battle Hot Stock Minute |
| 08:32AM | Biotech Stock Crashes After FDA Requires Additional Data For New Drug Application Business Insider |
| 08:00AM | Sarepta Therapeutics Announces Regulatory Update on Eteplirsen Call scheduled for 8:00 am ET today CCBN |
| 07:36AM | Sarepta timeline delayed on muscular dystrophy drug at CNBC |
| 07:20AM | Wall Street struggles to keep up momentum; Merck's profit tops estimates; Apple Pay gets a setback Hot Stock Minute |
| 07:04AM | SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 07:00AM | Sarepta Therapeutics Announces Regulatory Update on Eteplirsen Business Wire |
| Oct-24-14 02:58PM | Ebola stocks mostly higher after virus confirmed in New York at MarketWatch |
| 10:53AM | Ebola's in New York; is the economy at risk? Yahoo Finance |
| Oct-21-14 06:45PM | Ebola vaccine could be ready in 3 months: CEO at CNBC |
| Oct-20-14 10:44AM | Ebola outbreak: Cashing in on a cure Yahoo Finance |
| 06:10AM | A Promising Experimental Ebola Drug Goes Overlooked at BusinessWeek |
| Oct-17-14 12:00PM | 10 biggest financial-market events this week at MarketWatch |
| 10:58AM | Sarepta Therapeutics Shares Up On Ebola Drug Safety Study Benzinga |
| 09:11AM | Carnival slides on Ebola fears; Urban Outfitters tumbles on sales warning; Morgan Stanley blows past estimates Hot Stock Minute |
| 07:39AM | Ahead of the Bell: Sarepta Therapeutics climbs AP |
| 07:27AM | Sarepta Is Surging After Good News For Its Ebola Treatment Business Insider |
| 07:11AM | Stocks soar after volatile week; Housing starts rebounds; Starbucks offering free coffee and more Hot Stock Minute |
| Oct-16-14 07:38PM | [$$] Sarepta's Ebola Drug Showed No Ill Effects in Study at The Wall Street Journal +6.65% |
